NEVER MISS A STORY: GET THE PIX11 NEWS APP FOR IMPORTANT UPDATES

Turing reneges on drug price cut, rival’s version sells well

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

TRENTON, N.J. — After weeks of criticism from patients, doctors and even other drugmakers for hiking a life-saving medicine’s price more than fifty-fold, Turing Pharmaceuticals is reneging on its pledge to cut the $750-per-pill price.

Instead, the small biotech company says it’s reducing the price for hospitals by up to 50 percent for its Daraprim, which treats a rare parasitic infection that mainly strikes pregnant women and HIV patients.

The 62-year-old drug had no competition until a furor over the gigantic price hike erupted, triggering multiple government investigations.

Then a pharmacy that compounds prescription drugs for individual patients stepped in and started selling a capsule version for 99 cents. Imprimis Pharmaceuticals says orders are pouring in from doctors and it says it has dispensed more than 2,500 capsules in barely a month.